Production (Stage)
Century Therapeutics, Inc.
IPSC
$0.5834
$0.0081.39%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 109.16M | 4.17M | 791.00K | 771.00K | 855.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 109.16M | 4.17M | 791.00K | 771.00K | 855.00K |
| Cost of Revenue | 26.58M | 29.38M | 27.23M | 27.22M | 23.42M |
| Gross Profit | 82.58M | -25.20M | -26.44M | -26.45M | -22.57M |
| SG&A Expenses | 8.41M | 9.11M | 8.35M | 8.31M | 8.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.99M | 38.49M | 35.58M | 35.53M | 32.16M |
| Operating Income | 74.18M | -34.31M | -34.79M | -34.76M | -31.31M |
| Income Before Tax | 76.56M | -34.30M | -31.23M | -31.19M | -28.06M |
| Income Tax Expenses | -- | 1.78M | -8.00K | 22.00K | 1.00K |
| Earnings from Continuing Operations | 76.56M | -36.07M | -31.23M | -31.21M | -28.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.56M | -36.07M | -31.23M | -31.21M | -28.06M |
| EBIT | 74.18M | -34.31M | -34.79M | -34.76M | -31.31M |
| EBITDA | 77.40M | -31.00M | -31.49M | -31.29M | -28.08M |
| EPS Basic | 0.89 | -0.42 | -0.37 | -0.38 | -0.45 |
| Normalized Basic EPS | 0.56 | -0.23 | -0.23 | -0.24 | -0.28 |
| EPS Diluted | 0.89 | -0.42 | -0.37 | -0.38 | -0.45 |
| Normalized Diluted EPS | 0.56 | -0.23 | -0.23 | -0.24 | -0.28 |
| Average Basic Shares Outstanding | 86.02M | 85.41M | 84.70M | 82.09M | 62.30M |
| Average Diluted Shares Outstanding | 86.10M | 85.41M | 84.70M | 82.09M | 62.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |